STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.

Overview

Voyager Therapeutics Inc (VYGR) is a biotechnology company focused on developing innovative gene therapies for severe and debilitating diseases of the central nervous system (CNS). Using advanced AAV gene therapy techniques and its proprietary TRACER™ capsid discovery platform, Voyager is dedicated to overcoming traditional barriers in gene delivery and creating transformative solutions for neurological disorders.

Core Technology and Platform

The company leverages its TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform to engineer and optimize novel AAV capsids that are designed to cross the blood-brain barrier with high efficiency. This RNA-based screening enables rapid identification of capsid variants with enhanced CNS tropism and controlled tissue targeting, ensuring robust genetic payload delivery to areas of the brain traditionally hard to reach. The platform underpins both its gene therapy and antibody development programs, reflecting a robust integration of genetic science and neuroscience.

Pipeline and Disease Focus

Voyager Therapeutics maintains an extensive pipeline of programs aimed at addressing several critical CNS diseases. The company is developing gene therapy candidates to target conditions such as Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Additionally, Voyager is advancing therapies aimed at modifying the pathological processes in Alzheimer’s disease through tau silencing and anti-tau antibodies. Each candidate is carefully designed to modulate protein expression in the CNS, aiming to slow disease progression and improve patient outcomes.

Research and Development Approach

Emphasizing rigorous process development and production scalability, Voyager invests heavily in vector optimization and sophisticated dosing techniques. The company conducts cross-species preclinical studies to ensure that its TRACER-generated capsids achieve widespread and efficient gene expression while minimizing off-target effects. Its commitment to scientific excellence is reflected in its strategic external collaborations, which not only validate its technology but also extend its reach within the neurogenetic medicines field.

Industry Significance and Competitive Position

Voyager Therapeutics distinguishes itself within the biotechnology landscape through its specialized focus on CNS diseases and its innovative AAV-based gene therapy solutions. By integrating cutting-edge gene editing methodologies with deep neuroscientific insights, the company fills a significant unmet need in neurological drug development. Its collaboration with established industry partners further underscores the scientific reliability, stringent development standards, and translational potential of its candidates. The company’s balanced portfolio and technology-driven approach position it as a critical contributor to the evolution of gene therapies for challenging neurological conditions.

Commitment to Innovation and Patient Impact

At the heart of Voyager Therapeutics’ mission is the goal of modifying the course of devastating neurological diseases. By focusing on durable gene expression attainable through a single administration, the company aims to provide long-lasting therapeutic benefits that can transform the quality of life for patients. Its efforts in process development and clinical standardization continue to set benchmarks within the field, reflecting a commitment to excellence that is both scientifically robust and patient-centered.

This comprehensive approach—encompassing advanced vector engineering, strategic collaborations, and meticulous clinical development—underscores Voyager Therapeutics’ prominence in the realm of neurogenetic medicines and offers a detailed perspective for investors and industry observers alike.

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) will release its second quarter 2022 financial and operational results after the market closes on August 4, 2022. A live conference call and webcast will occur at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join the call by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international). A replay will be available for at least 30 days on its Investors website. Voyager Therapeutics focuses on developing AAV gene therapy treatments for serious diseases with its proprietary TRACER™ capsid platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
conferences
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) has appointed Catherine J. Mackey, Ph.D., to its Board of Directors, effective August 15, 2022. Dr. Mackey brings over 30 years of experience, notably at Pfizer, where she led R&D initiatives. Her expertise in strategic collaborations is expected to enhance Voyager's TRACER capsid discovery platform and pipeline development. CEO Al Sandrock emphasized the significance of Dr. Mackey's appointment at this pivotal moment for the company, aiming to leverage her knowledge for advancing AAV gene therapy solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
management
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) recently presented promising preclinical data on its TRACER capsid platform at the ASGCT Annual Meeting. The novel AAV9-derived capsid, VCAP-102, showed significant enhancements in brain transduction—60-fold in non-human primates and 50-fold in mice—compared to conventional AAV9 capsids. The data indicate potential therapeutic benefits for CNS disorders, including GBA1, tauopathies, and SOD1 ALS. These advances support Voyager's ongoing gene therapy developments aimed at improving treatment for patients with severe neurological conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced promising preclinical findings on its anti-HER2 antibody program at the ASGCT Annual Meeting. The TRACER AAV9 variant, VCAP-102, significantly reduced CNS tumor burden and enhanced survival in mouse models of HER2+ breast cancer, achieving a median survival of 129 days compared to 94 days for controls. Additionally, a novel AAV5-derived variant, VCAP-100, showed improved CNS transduction in non-human primates, indicating its potential for clinical development in CNS-targeted gene therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
conferences clinical trial
-
Rhea-AI Summary

Voyager Therapeutics (VYGR) presents significant advancements at the ASGCT Annual Meeting, showcasing preclinical data on its novel TRACER™ AAV capsids, demonstrating enhanced CNS tropisms and cross-species translatability. Key highlights include a license agreement with Novartis, providing $54 million upfront for potential CNS applications. The company reported Q1 2022 revenues of $0.7 million, down from $6.5 million YoY, and a net loss of $21.3 million. Strong cash position of $166.8 million expected to fund operations into 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.54%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) has announced nine presentations for the upcoming ASGCT 2022 meeting from May 16-19 in Washington, D.C. Highlights include new findings on TRACER™-generated AAV capsids, focusing on glial cell tropism, and a novel vectorized antibody approach targeting metastatic breast cancer. Notable presentations will cover improvements in CNS-targeted AAV vectors and gene therapies for ALS and other neurological diseases. CEO Al Sandrock emphasized the importance of these data in shaping Voyager's pipeline strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.14%
Tags
none
Rhea-AI Summary

Voyager Therapeutics announces the appointment of Dr. Alfred W. Sandrock, Jr. as CEO, succeeding Michael Higgins who served as interim CEO since June 2021. Dr. Sandrock, a prominent neuroscientist with a strong background in therapeutic development, aims to enhance Voyager's efforts in AAV gene therapy. His leadership is expected to drive advancements in Voyager's TRACER™ capsid discovery platform, potentially broadening applications for various diseases. The company is focused on achieving human proof of concept for its internal pipeline and has established licensing agreements with major pharmaceutical firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
management
-
Rhea-AI Summary

Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced a license option agreement with Novartis for access to its TRACER™ AAV capsids, targeting three CNS applications and options for two additional targets. This deal, alongside a previous Pfizer agreement, extends Voyager's cash runway into 2024 with total upfront payments of $84 million. The company reported a net income of $5.7 million for Q4 2021, improving from a loss in Q4 2020. However, the full year net loss was $71.2 million, primarily due to terminated collaborations. Leadership changes include the appointment of Al Sandrock, Jr. to the Board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics has entered a significant agreement with Novartis, receiving $54 million upfront and potential milestone payments up to $1.7 billion. The deal allows Novartis access to Voyager's TRACER AAV capsids for three central nervous system (CNS) targets, with options for two more. Voyager could also gain royalties from product sales. The TRACER platform is expected to enhance gene therapy delivery, reducing toxicity risks. This follows a previous collaboration with Pfizer, emphasizing Voyager’s growing capabilities in AAV gene therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
none
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR), a gene therapy innovator, has announced its participation in two upcoming virtual investor conferences. The company will present at the SVB Leerink 11th Annual Global Healthcare Conference on Feb. 18, 2022, at 9:20 a.m. ET, and participate in a corporate panel at the Cowen 42nd Annual Health Care Conference on Mar. 9, 2022, at 12:50 p.m. ET. Investors can access the sessions on Voyager's website and replays will be available for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
conferences

FAQ

What is the current stock price of Voyager Therapeutics (VYGR)?

The current stock price of Voyager Therapeutics (VYGR) is $3.37 as of April 1, 2025.

What is the market cap of Voyager Therapeutics (VYGR)?

The market cap of Voyager Therapeutics (VYGR) is approximately 185.2M.

What is the primary focus of Voyager Therapeutics?

Voyager Therapeutics is dedicated to developing gene therapies for severe neurological diseases using innovative AAV platforms and advanced vector engineering.

What is the TRACER™ platform?

The TRACER™ platform is an RNA-based screening technology that enables rapid discovery and optimization of AAV capsids for improved blood-brain barrier penetration and targeted CNS delivery.

Which central nervous system diseases does Voyager address?

Voyager’s pipeline includes therapies for Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, and Alzheimer’s disease, among other CNS conditions.

How does Voyager’s technology enhance gene delivery to the brain?

Their engineered AAV capsids are designed to cross the blood-brain barrier efficiently, target specific cell types, and achieve robust gene expression while limiting off-target transduction.

What distinguishes Voyager Therapeutics from other biotech companies?

Voyager is distinguished by its specialized focus on CNS diseases, its proprietary TRACER™ capsid discovery platform, and its commitment to integrating advanced gene therapy approaches with deep neuroscientific expertise.

Does Voyager collaborate with other organizations?

Yes, Voyager has strategic collaborations with established biotech firms, enhancing the scientific rigor and translational impact of its gene therapy candidates.

How do Voyager's therapies aim to impact patient treatment?

Their gene therapy candidates are designed to modify the underlying disease mechanisms by regulating protein expression, potentially slowing disease progression and improving patient quality of life.

What research methods support Voyager's development approach?

Voyager employs cross-species preclinical studies, advanced vector optimization, and robust process development to validate the safety and efficacy of its therapies.
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

185.22M
45.58M
17%
63.9%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON